ARA-290: Dosage, Benefits, FDA Status & Clinics (2026)

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Rotate injection sites with every administration and apply ice to the site for 60 seconds before injection. Persistent reactions (redness lasting >48 hours, induration, pain) occur in fewer than 5% of users but indicate localized immune response or repeated trauma to the same subcutaneous area. Switch to a different anatomical region entirely. If using the abdomen, move to the anterior thigh. If reactions persist across multiple sites, this may signal peptide contamination or hypersensitivity; discontinue and consult the prescribing researcher.

Order all peptide needed from a single production batch and verify the lot number matches across vials. Peptide synthesis variability between batches. Even from the same supplier. Can introduce 2–5% purity differences that alter receptor-binding kinetics. Real Peptides archives reference samples from each batch for 36 months, allowing researchers to reorder from the exact synthesis run if additional material is needed mid-study. Competitors using contract manufacturers often cannot guarantee batch matching because production occurs in response to demand rather than as controlled lots.

No. Administer the missed dose as soon as you remember within 24 hours, then return to your regular schedule. If more than 24 hours have passed since the missed dose, skip it entirely and continue with your next scheduled injection. Doubling doses does not compensate for missed time and increases the risk of injection site reactions without additional therapeutic benefit. The three-times-weekly schedule is designed around IRR activation kinetics. Missing one dose creates a brief gap in signaling but does not erase prior progress. Patients in the ACTION trial who missed fewer than two consecutive doses showed no difference in final outcomes compared to those with perfect adherence.

Mild erythema and transient swelling at the injection site occur in approximately 10–15% of users and typically resolve within 4–6 hours. This is a localized immune response to the peptide bolus, not an allergic reaction. Rotate injection sites with each dose, avoid injecting into the same quadrant within 72 hours, and ensure the reconstituted solution has reached room temperature before injecting. Cold peptide solutions cause more irritation. Persistent swelling lasting beyond 12 hours or spreading beyond the injection site warrants discontinuation and consultation.